Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: The objective of this work was to detect the markers of metabolic syndrome and insulin resistance in patients with PD and to study their impact on motor and cognitive symptoms.
Background: There is strong evidence that Parkinson’s disease (PD) and type 2 diabetes mellitus (DM) share many similar dysregulated pathways suggesting common underlying pathological mechanisms. The presence of DM in patients with PD was also found to accelerate progression of both motor and cognitive symptoms.
Method: The study was conducted on 37 patients fulfilled the criteria for diagnosis of idiopathic PD based on British Brain Bank criteria, and 27 healthy controls. Motor function for the included patients was assessed using Unified Parkinson’s disease Rating Scale (UPDRS). Cognitive function was assessed using PD-Cognitive Rating Scale (PD-CRS). Fasting blood sugar, triglycerides, high density lipoprotein, fasting insulin level (FI), Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) were measured for all included patients and controls.
Results: PD patients were found to have significantly higher levels of FI (P-value= 0.003) and HOMA-IR (P-value= 0.003) than controls. The frequency of metabolic syndrome was higher in PD patients than controls (χ2 =7.752, P-value= 0.005, OR=4.385, 95% CI=1.51-12.74). PD patients with metabolic syndrome were found to have significantly higher scores of UPDRS (P-value= 0.012) and lower scores of PD-CRS (P-value= 0.006) than those without metabolic syndrome. There was a statistically significant positive correlation between UPDRS scores and both FI level (r coef.=0.809, P-value˂0.001) and HOMA-IR (r coef.= 0.726, P-value˂0.001). There was a statistically significant negative correlation between PD-CRS scores and both FI level (r coef.= -0.698, P-value˂0.001) and HOMA-IR (r coef.= -0.652, P-value ˂ 0.001).
Conclusion: The incidence of both metabolic syndrome and insulin resistance is higher in patients with PD than healthy controls and their presence significantly affect both motor and cognitive symptoms in patients with PD.
To cite this abstract in AMA style:
M. Hussein, A. Khamis, R. Soliman, S. Ali. Metabolic syndrome and insulin resistance in Parkinson’s disease: could they affect motor or cognitive symptoms? [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/metabolic-syndrome-and-insulin-resistance-in-parkinsons-disease-could-they-affect-motor-or-cognitive-symptoms/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/metabolic-syndrome-and-insulin-resistance-in-parkinsons-disease-could-they-affect-motor-or-cognitive-symptoms/